We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for These 5 Medical Companies This Earnings Season?
Read MoreHide Full Article
Key Takeaways
Ironwood Pharmaceuticals sales seen at $52.79M, driven by Linzess partnership with AbbVie.
Novavax revenues eyed at $78.41M, driven by Sanofi license and Matrix-M royalties.
VTRS revenues seen at $3.52B, hit by normal product seasonality in the fourth quarter across all regions.
The fourth-quarter 2025 earnings season for the Medical sector is nearing its close, with just a few pharma and biotech companies left to report. Overall, the sector has delivered a fairly solid performance so far.
Per the Earnings Trends report, as of Feb. 18, 90% of the companies in the Medical sector — representing 98.2% of the sector’s market capitalization — reported quarterly earnings. Of these, 77.8% exceeded both earnings and sales estimates. Earnings decreased 0.2% year over year, while revenues increased 10.5%.
Among the pharma bigwigs that have reported results, Johnson & Johnson reported strong fourth-quarter results, beating estimates for both earnings and sales. Swiss pharma giant Novartis beat on earnings, but revenues were under pressure due to generic competition for key drugs like Entresto and Promacta.
Biotech giant Bristol Myers Squibb beat on both earnings and sales and issued an encouraging guidance. Gilead Sciences’ earnings beat the top and bottom lines, aided by higher HIV and liver diseases drugs. Fourth-quarter earnings in the medical sector are expected to decrease 0.1%, while sales are projected to rise 10.4% from the year-ago quarter.
Ironwood Pharmaceuticals (IRWD - Free Report) , Recursion Pharmaceuticals (RXRX - Free Report) , Novavax (NVAX - Free Report) , Viatris (VTRS - Free Report) and Intellia Therapeutics (NTLA - Free Report) are all slated to release theirquarterly results this week. Let us examine how these biotech/pharma companies are likely to have performed in the soon-to-be-reported quarter.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals’ performance has been mixed, with the company exceeding earnings expectations in two of the trailing four quarters and missing the same on the remaining two occasions. It delivered a four-quarter earnings surprise of 176.67%, on average. In the last reported quarter, IRWD delivered an earnings surprise of 166.67%.
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of delivering an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Ironwood Pharmaceuticals has an Earnings ESP of 0.00% and sports a Zacks Rank #1 at present. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $52.79 million and 2 cents per share, respectively. You can see the complete list of today’s Zacks #1 Rank stocks here.
Ironwood Pharmaceuticals’ revenues in the fourth quarter are likely to have been driven by the sales of its sole commercialized product, Linzess (linaclotide), which it markets in partnership with AbbVie in the United States.
Ironwood Pharmaceuticals is scheduled to release its quarterly earnings results before the opening bell on Feb. 25.
Ironwood Pharmaceuticals, Inc. Price and Consensus
Recursion Pharmaceuticals has a mixed earnings surprise history so far. The company missed estimates in three of the trailing four reported quarters, beating on the remaining occasion, delivering an average negative surprise of 18.19%. In the last reported quarter, the company delivered a surprise of 5.26%.
Recursion Pharmaceuticals has an Earnings ESP of 0.00% and a Zacks Rank #2 at present. The Zacks Consensus Estimate for revenues and loss per share for the fourth quarter is pegged at $25.50 million and 28 cents, respectively.
In the absence of a marketed product, Recursion Pharmaceuticals only recognizes collaboration and grant revenues from its partners. The company is expected to provide updates regarding the clinical-stage pipeline programs on its fourth-quarter earnings call. Recursion Pharmaceuticals’ lead candidate, REC-4881, is being evaluated in a phase Ib/II TUPELO study for familial adenomatous polyposis.
Recursion Pharmaceuticals is scheduled to release its quarterly earnings results before the opening bell on Feb. 25.
Recursion Pharmaceuticals, Inc. Price and Consensus
Novavax has an impeccable earnings surprise history so far. The company beat estimates in each of the trailing four reported quarters, delivering an average surprise of 343.25%. In the last reported quarter, the company delivered a surprise of 42.59%.
Novavax has an Earnings ESP of 0.00% and a Zacks Rank #2 at present. The Zacks Consensus Estimate for revenues and loss per share for the fourth quarter is pegged at $78.41 million and 66 cents, respectively.
Novavax’s revenues in the fourth quarter are likely to have been driven by Licensing, royalties and other revenues, following a non-exclusive license agreement with Sanofi to use its proprietary Matrix-M adjuvant in vaccine products. NVAX’s product sales are likely to have provided incremental revenues, adding to the top line.
Novavax is scheduled to release its quarterly earnings results before the opening bell on Feb. 26.
Viatris’ performance has been mixed, with the company exceeding earnings expectations in three of the trailing four quarters and missing the same on the remaining occasion. It delivered a four-quarter earnings surprise of 3.46%, on average. In the last reported quarter, VTRS delivered an earnings surprise of 6.35%.
Viatris has an Earnings ESP of 0.00% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for revenues and earnings per share for the fourth quarter is pegged at $3.52 billion and 52 cents, respectively.
Viatris’ total revenues are likely to have declined across all geographical segments due to normal product seasonality in the fourth quarter. Brand performance is likely to have benefited from strong performance in Greater China and Emerging Markets, in addition to growth in certain key brands in Developed Markets. However, the generics business is likely to have been negatively impacted by inspection at the Indore facility and competition for Wixela.
Viatris is scheduled to release its quarterly earnings results before the opening bell on Feb. 26.
Intellia Therapeutics has an impeccable earnings surprise history so far. The company beat estimates in each of the trailing four reported quarters, delivering an average surprise of 8.11%. In the last reported quarter, the company delivered a surprise of 9.80%.
Intellia Therapeutics has an Earnings ESP of 0.00% and a Zacks Rank #4 (Sell) at present. The Zacks Consensus Estimate for revenues and loss per share for the fourth quarter is pegged at $11.85 million and 99 cents, respectively.
Intellia Therapeutics’total revenues currently comprise only collaboration revenues, which are expected to have declined on a year-over-year basis due to lower revenues from collaborators.
Intellia Therapeutics is scheduled to release its quarterly earnings results before the opening bell on Feb. 26.
View the Zacks #1 Rank List
Image: Bigstock
What's in Store for These 5 Medical Companies This Earnings Season?
Key Takeaways
The fourth-quarter 2025 earnings season for the Medical sector is nearing its close, with just a few pharma and biotech companies left to report. Overall, the sector has delivered a fairly solid performance so far.
Per the Earnings Trends report, as of Feb. 18, 90% of the companies in the Medical sector — representing 98.2% of the sector’s market capitalization — reported quarterly earnings. Of these, 77.8% exceeded both earnings and sales estimates. Earnings decreased 0.2% year over year, while revenues increased 10.5%.
Among the pharma bigwigs that have reported results, Johnson & Johnson reported strong fourth-quarter results, beating estimates for both earnings and sales. Swiss pharma giant Novartis beat on earnings, but revenues were under pressure due to generic competition for key drugs like Entresto and Promacta.
Biotech giant Bristol Myers Squibb beat on both earnings and sales and issued an encouraging guidance. Gilead Sciences’ earnings beat the top and bottom lines, aided by higher HIV and liver diseases drugs. Fourth-quarter earnings in the medical sector are expected to decrease 0.1%, while sales are projected to rise 10.4% from the year-ago quarter.
Ironwood Pharmaceuticals (IRWD - Free Report) , Recursion Pharmaceuticals (RXRX - Free Report) , Novavax (NVAX - Free Report) , Viatris (VTRS - Free Report) and Intellia Therapeutics (NTLA - Free Report) are all slated to release theirquarterly results this week. Let us examine how these biotech/pharma companies are likely to have performed in the soon-to-be-reported quarter.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals’ performance has been mixed, with the company exceeding earnings expectations in two of the trailing four quarters and missing the same on the remaining two occasions. It delivered a four-quarter earnings surprise of 176.67%, on average. In the last reported quarter, IRWD delivered an earnings surprise of 166.67%.
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of delivering an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Ironwood Pharmaceuticals has an Earnings ESP of 0.00% and sports a Zacks Rank #1 at present. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $52.79 million and 2 cents per share, respectively. You can see the complete list of today’s Zacks #1 Rank stocks here.
Ironwood Pharmaceuticals’ revenues in the fourth quarter are likely to have been driven by the sales of its sole commercialized product, Linzess (linaclotide), which it markets in partnership with AbbVie in the United States.
Ironwood Pharmaceuticals is scheduled to release its quarterly earnings results before the opening bell on Feb. 25.
Ironwood Pharmaceuticals, Inc. Price and Consensus
Ironwood Pharmaceuticals, Inc. price-consensus-chart | Ironwood Pharmaceuticals, Inc. Quote
Recursion Pharmaceuticals
Recursion Pharmaceuticals has a mixed earnings surprise history so far. The company missed estimates in three of the trailing four reported quarters, beating on the remaining occasion, delivering an average negative surprise of 18.19%. In the last reported quarter, the company delivered a surprise of 5.26%.
Recursion Pharmaceuticals has an Earnings ESP of 0.00% and a Zacks Rank #2 at present. The Zacks Consensus Estimate for revenues and loss per share for the fourth quarter is pegged at $25.50 million and 28 cents, respectively.
In the absence of a marketed product, Recursion Pharmaceuticals only recognizes collaboration and grant revenues from its partners. The company is expected to provide updates regarding the clinical-stage pipeline programs on its fourth-quarter earnings call. Recursion Pharmaceuticals’ lead candidate, REC-4881, is being evaluated in a phase Ib/II TUPELO study for familial adenomatous polyposis.
Recursion Pharmaceuticals is scheduled to release its quarterly earnings results before the opening bell on Feb. 25.
Recursion Pharmaceuticals, Inc. Price and Consensus
Recursion Pharmaceuticals, Inc. price-consensus-chart | Recursion Pharmaceuticals, Inc. Quote
Novavax
Novavax has an impeccable earnings surprise history so far. The company beat estimates in each of the trailing four reported quarters, delivering an average surprise of 343.25%. In the last reported quarter, the company delivered a surprise of 42.59%.
Novavax has an Earnings ESP of 0.00% and a Zacks Rank #2 at present. The Zacks Consensus Estimate for revenues and loss per share for the fourth quarter is pegged at $78.41 million and 66 cents, respectively.
Novavax’s revenues in the fourth quarter are likely to have been driven by Licensing, royalties and other revenues, following a non-exclusive license agreement with Sanofi to use its proprietary Matrix-M adjuvant in vaccine products. NVAX’s product sales are likely to have provided incremental revenues, adding to the top line.
Novavax is scheduled to release its quarterly earnings results before the opening bell on Feb. 26.
Novavax, Inc. Price and Consensus
Novavax, Inc. price-consensus-chart | Novavax, Inc. Quote
Viatris
Viatris’ performance has been mixed, with the company exceeding earnings expectations in three of the trailing four quarters and missing the same on the remaining occasion. It delivered a four-quarter earnings surprise of 3.46%, on average. In the last reported quarter, VTRS delivered an earnings surprise of 6.35%.
Viatris has an Earnings ESP of 0.00% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for revenues and earnings per share for the fourth quarter is pegged at $3.52 billion and 52 cents, respectively.
Viatris’ total revenues are likely to have declined across all geographical segments due to normal product seasonality in the fourth quarter. Brand performance is likely to have benefited from strong performance in Greater China and Emerging Markets, in addition to growth in certain key brands in Developed Markets. However, the generics business is likely to have been negatively impacted by inspection at the Indore facility and competition for Wixela.
Viatris is scheduled to release its quarterly earnings results before the opening bell on Feb. 26.
Viatris Inc. Price and Consensus
Viatris Inc. price-consensus-chart | Viatris Inc. Quote
Intellia Therapeutics
Intellia Therapeutics has an impeccable earnings surprise history so far. The company beat estimates in each of the trailing four reported quarters, delivering an average surprise of 8.11%. In the last reported quarter, the company delivered a surprise of 9.80%.
Intellia Therapeutics has an Earnings ESP of 0.00% and a Zacks Rank #4 (Sell) at present. The Zacks Consensus Estimate for revenues and loss per share for the fourth quarter is pegged at $11.85 million and 99 cents, respectively.
Intellia Therapeutics’total revenues currently comprise only collaboration revenues, which are expected to have declined on a year-over-year basis due to lower revenues from collaborators.
Intellia Therapeutics is scheduled to release its quarterly earnings results before the opening bell on Feb. 26.
Intellia Therapeutics, Inc. Price and Consensus
Intellia Therapeutics, Inc. price-consensus-chart | Intellia Therapeutics, Inc. Quote